Clinical Trial Update: Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating bozitinib in combination with chemotherapy as a radical treatment for MET-altered non-small cell lung cancer (stages IIA-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bozitinib (bozitinib)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: NSCLC, MET Exon 14 Mutation | Phase 2 | Status: NOT_YET_RECRUITING